Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.02
-0.14 (-2.71%)
At close: Apr 28, 2026, 4:00 PM EDT
5.02
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
70
Market Cap
1.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 257.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 400.00K | 346.00K | 640.74% |
| Dec 31, 2015 | 54.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 300.00K | -200.00K | -40.00% |
| Dec 31, 2008 | 500.00K | - | - |
| Dec 31, 2007 | 500.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| AbCellera Biologics | 75.13M |
| Viridian Therapeutics | 70.85M |
| Wave Life Sciences | 42.73M |
| Precigen | 9.68M |
| DBV Technologies | 5.64M |
SVRA News
- 11 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 13 days ago - Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 14 days ago - Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - Business Wire
- 21 days ago - Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 4 weeks ago - Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 6 weeks ago - Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Savara Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire